Trace amine-associated receptor 1 as a monoaminergic modulator in brain

Biochemical Pharmacology

Volumn 78, Issue 9, 2009, Pages 1095-1104

  Xie, Zhihua ^a   Miller, Gregory M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Methamphetamine; Monoamine transporter; Monoaminergic system; Psychostimulant; Trace amine associated receptor; Trace amines

Indexed keywords

AMPHETAMINE; BIOGENIC AMINE; BRAIN MONOAMINE; CYCLIC AMP; DOPAMINE; DOPAMINE TRANSPORTER; G PROTEIN COUPLED RECEPTOR; MESSENGER RNA; METHAMPHETAMINE; NORADRENALIN; OCTOPAMINE; PHENETHYLAMINE; SEROTONIN; TRACE AMINE ASSOCIATED RECEPTOR 1; TRYPTAMINE; TYRAMINE; UNCLASSIFIED DRUG;

ARTICLE; ATTENTION; BRAIN FUNCTION; BRAIN REGION; BRAIN SYNAPTOSOME; CELLULAR DISTRIBUTION; COGNITION; DOPAMINERGIC NERVE CELL; DRUG TARGETING; EMOTIONALITY; HUMAN; LEARNING; MENTAL DISEASE; MOLECULAR CLONING; MONOAMINERGIC SYSTEM; MOOD; MOUSE; NEUROLOGIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; RECEPTOR UPREGULATION; REWARD; RHESUS MONKEY; SIGNAL TRANSDUCTION; SPECIES DIFFERENCE; SUBSTANTIA NIGRA;

ANIMALS; BIOGENIC MONOAMINES; BRAIN; CLONING, MOLECULAR; HUMANS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 70249093584     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2009.05.031     Document Type: Note

References (79)

1. Borowsky B., Adham N., Jones K.A., Raddatz R., Artymyshyn R., Ogozalek K.L., et al. Trace amines: identification of a family of mammalian G protein-coupled receptors. Proc Natl Acad Sci USA 98 (2001) 8966-8971
2. Lindemann L., Ebeling M., Kratochwil N.A., Bunzow J.R., Grandy D.K., and Hoener M.C. Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors. Genomics 85 (2005) 372-385
3. Bunzow J.R., Sonders M.S., Arttamangkul S., Harrison L.M., Zhang G., Quigley D.I., et al. Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. Mol Pharmacol 60 (2001) 1181-1188
4. Miller G.M., Verrico C.D., Jassen A., Konar M., Yang H., Panas H., et al. Primate trace amine receptor 1 modulation by the dopamine transporter. J Pharmacol Exp Ther 313 (2005) 983-994
5. Gloriam D.E., Bjarnadottir T.K., Yan Y.L., Postlethwait J.H., Schioth H.B., and Fredriksson R. The repertoire of trace amine G-protein-coupled receptors: large expansion in zebrafish. Mol Phylogenet Evol 35 (2005) 470-482
6. Cao Q., Martinez M., Zhang J., Sanders A.R., Badner J.A., Cravchik A., et al. Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics 43 (1997) 1-8
7. Levinson D.F., Holmans P., Straub R.E., Owen M.J., Wildenauer D.B., Gejman P.V., et al. Multicenter linkage study of schizophrenia candidate regions on chromosomes 5q, 6q, 10p, and 13q: schizophrenia linkage collaborative group III. Am J Hum Genet 67 (2000) 652-663
8. Grandy D.K. Trace amine-associated receptor 1-family archetype or iconoclast?. Pharmacol Ther 116 (2007) 355-390
9. Xie Z., Westmoreland S.V., Bahn M.E., Chen G.L., Yang H., Vallender E.J., et al. Rhesus monkey trace amine-associated receptor 1 signaling: enhancement by monoamine transporters and attenuation by the D2 autoreceptor in vitro. J Pharmacol Exp Ther 321 (2007) 116-127
10. Lindemann L., Meyer C.A., Jeanneau K., Bradaia A., Ozmen L., Bluethmann H., et al. Trace amine-associated receptor 1 modulates dopaminergic activity. J Pharmacol Exp Ther 324 (2008) 948-956
11. Crossman A.R. Gray's anatomy: the anatomical basis of clinical practice. In: Standring S. (Ed). Brain stem (2005), Churchill Livingston, Edinburgh 327-351
12. Haines D.E. Fundamental neuroscience for basic and clinical applications (2006), Elsevier, Philadelphia
13. Martin A.R., Wallace B.G., Fuchs P.A., and Nicholls J.G. From neuron to brain (2001), Sinauer Associates, Sunderland
14. Nieuwenhuys R., Voogd J., and Van Huijzen C. The human central nervous system (2008), Springer, Berlin p. 889-916
15. Schultz W. Getting formal with dopamine and reward. Neuron 36 (2002) 241-263
16. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 67 (2002) 53-83
17. Centonze D., Grande C., Saulle E., Martin A.B., Gubellini P., Pavon N., et al. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J Neurosci 23 (2003) 8506-8512
18. Denenberg V.H., Kim D.S., and Palmiter R.D. The role of dopamine in learning, memory, and performance of a water escape task. Behav Brain Res 148 (2004) 73-78
19. Cools R. Role of dopamine in the motivational and cognitive control of behavior. Neuroscientist 14 (2008) 381-395
20. Hurlemann R., Hawellek B., Matusch A., Kolsch H., Wollersen H., Madea B., et al. Noradrenergic modulation of emotion-induced forgetting and remembering. J Neurosci 25 (2005) 6343-6349
21. Gottesmann C. Noradrenaline involvement in basic and higher integrated REM sleep processes. Prog Neurobiol 85 (2008) 237-272
22. van Stegeren A.H. The role of the noradrenergic system in emotional memory. Acta Psychol (Amst) 127 (2008) 532-541
23. Halford J.C., Harrold J.A., Boyland E.J., Lawton C.L., and Blundell J.E. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 67 (2007) 27-55
24. Saitow F., Murano M., and Suzuki H. Modulatory effects of serotonin on GABAergic synaptic transmission and membrane properties in the deep cerebellar nuclei. J Neurophysiol 101 (2009) 1361-1374
25. Barnes N.M., and Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 38 (1999) 1083-1152
26. Hoyer D., Hannon J.P., and Martin G.R. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71 (2002) 533-554
27. Zucchi R., Chiellini G., Scanlan T.S., and Grandy D.K. Trace amine-associated receptors and their ligands. Br J Pharmacol 149 (2006) 967-978
28. Hart M.E., Suchland K.L., Miyakawa M., Bunzow J.R., Grandy D.K., and Scanlan T.S. Trace amine-associated receptor agonists: synthesis and evaluation of thyronamines and related analogues. J Med Chem 49 (2006) 1101-1112
29. Wainscott D.B., Little S.P., Yin T., Tu Y., Rocco V.P., He J.X., et al. Pharmacologic characterization of the cloned human trace amine-associated receptor1 (TAAR1) and evidence for species differences with the rat TAAR1. J Pharmacol Exp Ther 320 (2007) 475-485
30. Reese E.A., Bunzow J.R., Arttamangkul S., Sonders M.S., and Grandy D.K. Trace amine-associated receptor 1 displays species-dependent stereoselectivity for isomers of methamphetamine, amphetamine, and para-hydroxyamphetamine. J Pharmacol Exp Ther 321 (2007) 178-186
31. Bergman J., Yasar S., and Winger G. Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors. Psychopharmacology (Berl) 159 (2001) 21-30
32. Xie Z., Westmoreland S.V., and Miller G.M. Modulation of monoamine transporters by common biogenic amines via trace amine-associated receptor 1 and monoamine autoreceptors in human embryonic kidney 293 cells and brain synaptosomes. J Pharmacol Exp Ther 325 (2008) 629-640
33. Kish S.J. Pharmacologic mechanisms of crystal meth. CMAJ 178 (2008) 1679-1682
34. Rothman R.B., and Baumann M.H. Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479 (2003) 23-40
35. Scanlan T.S., Suchland K.L., Hart M.E., Chiellini G., Huang Y., Kruzich P.J., et al. 3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med 10 (2004) 638-642
36. Snead A.N., Santos M.S., Seal R.P., Miyakawa M., Edwards R.H., and Scanlan T.S. Thyronamines inhibit plasma membrane and vesicular monoamine transport. ACS Chem Biol 2 (2007) 390-398
37. Xie Z., Vallender E.J., Yu N., Kirstein S.L., Yang H., Bahn M.E., et al. Cloning, expression, and functional analysis of rhesus monkey trace amine-associated receptor 6: evidence for lack of monoaminergic association. J Neurosci Res 86 (2008) 3435-3446
38. Amara S.G., and Arriza J.L. Neurotransmitter transporters: three distinct gene families. Curr Opin Neurobiol 3 (1993) 337-344
39. Masson J., Sagne C., Hamon M., and El Mestikawy S. Neurotransmitter transporters in the central nervous system. Pharmacol Rev 51 (1999) 439-464
40. Gether U., Andersen P.H., Larsson O.M., and Schousboe A. Neurotransmitter transporters: molecular function of important drug targets. Trends Pharmacol Sci 27 (2006) 375-383
41. Uhl G.R., and Johnson P.S. Neurotransmitter transporters: three important gene families for neuronal function. J Exp Biol 196 (1994) 229-236
42. - neurotransmitter transporters. J Neurochem 71 (1998) 1785-1803
43. Blakely R.D., De Felice L.J., and Hartzell H.C. Molecular physiology of norepinephrine and serotonin transporters. J Exp Biol 196 (1994) 263-281
44. Moron J.A., Brockington A., Wise R.A., Rocha B.A., and Hope B.T. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 22 (2002) 389-395
45. Klimek V., Stockmeier C., Overholser J., Meltzer H.Y., Kalka S., Dilley G., et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci 17 (1997) 8451-8458
46. Arango V., Underwood M.D., and Mann J.J. Serotonin brain circuits involved in major depression and suicide. Prog. Brain Res 136 (2002) 443-453
47. Schmitt G.J., Frodl T., Dresel S., la Fougere C., Bottlender R., Koutsouleris N., et al. Striatal dopamine transporter availability is associated with the productive psychotic state in first episode, drug-naive schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 256 (2006) 115-121
48. Serretti A., Calati R., Mandelli L., and De Ronchi D. Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets 7 (2006) 1659-1669
49. Troiano A.R., de la Fuente-Fernandez R., Sossi V., Schulzer M., Mak E., Ruth T.J., et al. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 72 (2009) 1211-1216
50. Madras B.K., Xie Z., Lin Z., Jassen A., Panas H., Lynch L., et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319 (2006) 561-569
51. Booij J., and Knol R.J. SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. Parkinsonism Relat Disord 13 Suppl. 3 (2007) S425-S428
52. 123I]ADAM SPECT in a Parkinsonian primate model. Appl Radiat Isot 66 (2008) 1799-1803
53. Zipursky R.B., Meyer J.H., and Verhoeff N.P. PET and SPECT imaging in psychiatric disorders. Can J Psychiatry 52 (2007) 146-157
54. Bailey B.A., Philips S.R., and Boulton A.A. In vivo release of endogenous dopamine, 5-hydroxytryptamine and some of their metabolites from rat caudate nucleus by phenylethylamine. Neurochem Res 12 (1987) 173-178
55. Xie Z., and Miller G.M. Beta-phenylethylamine alters monoamine transporter function via trace amine-associated receptor 1: implication for modulatory roles of trace amines in brain. J Pharmacol Exp Ther 325 (2008) 617-628
56. Yatin S.M., Miller G.M., Norton C., and Madras B.K. Dopamine transporter-dependent induction of C-Fos in HEK cells. Synapse 45 (2002) 52-65
57. Tissari A.H., Rossetti Z.L., Meloni M., Frau M.I., and Gessa G.L. Autoreceptors mediate the inhibition of dopamine synthesis by bromocriptine and lisuride in rats. Eur J Pharmacol 91 (1983) 463-468
58. Starke K., Gothert M., and Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol Rev 69 (1989) 864-989
59. Gobert A., Rivet J.M., Cistarelli L., and Millan M.J. Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935. J Neurochem 68 (1997) 1159-1163
60. Yoshitake T., Yoshitake S., Yamaguchi M., Ogren S.O., and Kehr J. Activation of 5-HT(1A) autoreceptors enhances the inhibitory effect of galanin on hippocampal 5-HT release in vivo. Neuropharmacology 44 (2003) 206-213
61. Tavares A., Handy D.E., Bogdanova N.N., Rosene D.L., and Gavras H. Localization of alpha 2A- and alpha 2B-adrenergic receptor subtypes in brain. Hypertension 27 (1996) 449-455
62. Callado L.F., and Stamford J.A. Alpha2A- but not alpha2B/C-adrenoceptors modulate noradrenaline release in rat locus coeruleus: voltammetric data. Eur J Pharmacol 366 (1999) 35-39
63. Meiergerd S.M., Patterson T.A., and Schenk J.O. D2 receptors may modulate the function of the striatal transporter for dopamine: kinetic evidence from studies in vitro and in vivo. J Neurochem 61 (1993) 764-767
64. Cass W.A., and Gerhardt G.A. Direct in vivo evidence that D2 dopamine receptors can modulate dopamine uptake. Neurosci Lett 176 (1994) 259-263
65. Wolinsky T.D., Swanson C.J., Smith K.E., Zhong H., Borowsky B., Seeman P., et al. The trace amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia. Genes Brain Behav 6 (2007) 628-639
66. Xie Z., and Miller G.M. Trace amine-associated receptor 1 is a modulator of the dopamine transporter. J Pharmacol Exp Ther 321 (2007) 128-136
67. Hart C.L., Ward A.S., Haney M., Foltin R.W., and Fischman M.W. Methamphetamine self-administration by humans. Psychopharmacology (Berl) 157 (2001) 75-81
68. Cretzmeyer M., Sarrazin M.V., Huber D.L., Block R.I., and Hall J.A. Treatment of methamphetamine abuse: research findings and clinical directions. J Subst Abuse Treat 24 (2003) 267-277
69. Sulzer D., Sonders M.S., Poulsen N.W., and Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75 (2005) 406-433
70. Fleckenstein A.E., Volz T.J., Riddle E.L., Gibb J.W., and Hanson G.R. New insights into the mechanism of action of amphetamines. Annu Rev Pharmacol Toxicol 47 (2007) 681-698
71. Sulzer D., Chen T.K., Lau Y.Y., Kristensen H., Rayport S., and Ewing A. Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport. J Neurosci 15 (1995) 4102-4108
72. Sandoval V., Riddle E.L., Ugarte Y.V., Hanson G.R., and Fleckenstein A.E. Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model. J Neurosci 21 (2001) 1413-1419
73. Han D.D., and Gu H.H. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 6 (2006) 6
74. Cervinski M.A., Foster J.D., and Vaughan R.A. Psychoactive substrates stimulate dopamine transporter phosphorylation and down-regulation by cocaine-sensitive and protein kinase C-dependent mechanisms. J Biol Chem 280 (2005) 40442-40449
75. Johnson L.A., Furman C.A., Zhang M., Guptaroy B., and Gnegy M.E. Rapid delivery of the dopamine transporter to the plasmalemmal membrane upon amphetamine stimulation. Neuropharmacology 49 (2005) 750-758
76. Xie Z., and Miller G.M. A receptor mechanism for methamphetamine action in dopamine transporter regulation in brain. J Pharmacol Exp Ther (2009) [Epub ahead of print]
77. Giambalvo C.T. Mechanisms underlying the effects of amphetamine on particulate PKC activity. Synapse 51 (2004) 128-139
78. Zhang L., Coffey L.L., and Reith M.E. Regulation of the functional activity of the human dopamine transporter by protein kinase C. Biochem Pharmacol 53 (1997) 677-688
79. Melikian H.E., and Buckley K.M. Membrane trafficking regulates the activity of the human dopamine transporter. J Neurosci 19 (1999) 7699-7710